Mr. Guillermo Moreno reports

DIAGNOS ANNOUNCES A PILOT WITH HOSPITAL OFTALMOLOGICO BUENA VISTA SINALOA

Diagnos Inc. has signed a two-month pilot with Hospital Oftalmologico Buena Vista Sinaloa, the largest ophthalmological hospital in Sinaloa state, Mexico.

In Mexico there are 18 million diabetics with a 23-per-cent prevalence in people of 20 years or more; the seriousness of these cases is that every hour in the country eight patients die from this disease, since 80 per cent of deaths in Mexico are related to diabetes. In Sinaloa state, 355,000 cases are reported, of which almost half (175,000) are undiagnosed, with a prevalence of 21 per cent of the population of 20 years or more. Of the 180,000 diagnosed for diabetes, only 30 per cent go to the doctor on a regular basis. According to statistics, 30,000 new cases of diabetes per year are registered in the state of Sinaloa. Diabetic retinopathy and loss of vision are the two biggest problems.

"For almost 25 years, we've been providing ophthalmic eye care to hundreds of thousands of patients coming from four out of nine states of the northern region of Mexico, mainly the West Pacific area. Our focus is to provide our specialty services to everybody within one of our seven eye health programs such as ophthalmological consultation, surgeries, culture of prevention of eye diseases, campaign of free consultation in suburban areas to people in extreme poverty, national museum of ophthalmology, among others," mentions Dr. Efrain Romo Santos, founder and head of ophthalmology at Hospital Oftalmologico Buena Vista Sinaloa. "We're excited to welcome Diagnos as we look forward to use a real-life tested technology based on AI, reliable and compliant with the most exigent international standards," finished Dr. Romo.

"This is a great moment for Diagnos as we've been proving that our AI and telemedicine modules helps safety issues around specialists and their staff during this challenging time. We will be demonstrating our service of retina screening to everyone that needs it," says Guillermo Moreno, vice-president of Diagnos. "Along with Dr. Romo, we'll provide a turnkey solution to his renowned team of specialists. We're confident that during the pilot we'll deliver a real-time result to the local population by supporting the specialists in their day to day. Finally, we will give hope to patients through the access to eye screening with Dr. Romo's Institutions," finished Mr. Moreno.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the Food and Drug Administration (United States), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

We seek Safe Harbor.